| symbol |
NVTR |
|---|
| 会社名 | Nuvectra Corp （ヌベクトラ） |
|---|
| 分野（sector） |
Health Care
ヘルスケア
|
|---|
| 産業（industry） |
Medical/Dental Instruments
|
|---|
| 業種 |
バイオテクノロジ―_メディカルリサ―チ
医療関連（Health Care）
|
|---|
| 概要 |
事業概要 Nuvectra Corporation is a neurostimulation company that focuses on helping physicians to improve the lives of people with chronic neurological conditions. The Company''s Algovita Spinal Cord Stimulation (SCS) System (Algovita) is the Company''s commercial offering and is Conformite Europeene (CE) marked and the United States Food and Drug Administration (FDA) approved for the treatment of chronic pain of the trunk and/or limbs. Its technology platform also has capabilities under development to support other neurological indications such as sacral nerve stimulation (SNS) and deep brain stimulation (DBS). In addition its NeuroNexus Technologies Inc. (NeuroNexus) subsidiary designs manufactures and markets neural-interface technologies for the neuroscience clinical research market. Its Virtis is an application of the Company''s neurostimulation technology platform and its first product for the SNS market. Its subsidiaries include Algostim LLC (Algostim) and PelviStim LLC (PelviStim). ヌベクトラは米国の医療機器メ―カ―。主に痛みや障害治療向けの神経刺激技術プラットフォ―ムの開発・商業化に従事する。同社の技術は脊髄刺激療法(SCS)や脳深部刺激療法(DBS)などに使用され、「Algovita」は体幹と手足の慢性的な痛みを治療するために開発された最初の医療機器である。本社はテキサス州プレイノ。 Nuvectra Corp. is a neurostimulation medical device company, which engages in the development and commercialization of neurostimulation technology platform for treatment of various disorders through stimulation of tissues associated with the nervous systems. It operates through Nuvectra segment. The Nuvectra segment is a neurostimulation company committed to helping physicians improve the lives of people with chronic conditions. The company was founded on November 14, 2008 and is headquartered in Plano, TX.
|
|---|
| 本社所在地 | 5830 Granite Parkway Suite 1100 Plano TX 75024 USA |
|---|
| 代表者氏名 | ― |
|---|
| 代表者役職名 | ― |
|---|
| 電話番号 | +1 972-668-4107 |
|---|
| 設立年月日 | 39753 |
|---|
| 市場名 | NASDAQ National Market System |
|---|
| ipoyear | ―年 |
|---|
| 従業員数 | 195人 |
|---|
| url | www.nuvectramed.com |
|---|
| nasdaq_url | https://www.nasdaq.com/symbol/nvtr |
|---|
| adr_tso | ― |
|---|
| EBITDA | EBITDA（百万ドル） -37.39700 |
|---|
| 終値（lastsale） | 23.69 |
|---|
| 時価総額（marketcap） | 414792924.31 |
|---|
| 時価総額 | 時価総額（百万ドル） 355.07420 |
|---|
| 売上高 | 売上高（百万ドル） 43.29600 |
|---|
| 企業価値(EV) | 企業価値(EV)（百万ドル） 350.05420 |
|---|
| 当期純利益 | 当期純利益（百万ドル） -39.80800 |
|---|
| 決算概要 | 決算概要 BRIEF: For the 26 weeks ended 30 June 2018 Nuvectra Corp revenues increased 93% to $23.7M. Net loss decreased 8% to $22.3M. Revenues reflect Nuvectra segment increase from $9.9M to $21.4M. Lower net loss reflects Nuvectra segment loss decrease of 12% to $20.7M NeuroNexus segment income increase of 83% to $267K. Basic Earnings per Share excluding Extraordinary Items increased from -$2.34 to -$1.67. |
|---|
NVTR - ヌベクトラ （Nuvectra Corporation） ヌベクトラ